Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

OBJECTIVE: Stereotactic body radiotherapy (SBRT) has been shown to improve overall survival in patients with advanced hepatocellular carcinoma. This study aimed to assess the cost-effectiveness of SBRT compared to sorafenib which is the only drug for advanced hepatocellular carcinoma. METHODS: A Mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Henry W. C., Liu, Chung-Feng, Chan, Agnes L. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870794/
https://www.ncbi.nlm.nih.gov/pubmed/27193904
http://dx.doi.org/10.1186/s13014-016-0644-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870794/
https://www.ncbi.nlm.nih.gov/pubmed/27193904
http://dx.doi.org/10.1186/s13014-016-0644-4

Ejemplares similares